Navigation Links
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
Date:4/2/2009

BETHESDA, Md., April 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the filing of the first clinical trial application (CTA) in Europe by its partner Nycomed for the anti-GM-CSF antibody MT203. Micromet received a payment of 1.5 million Euro (US$ 2.0 million) from Nycomed for the achievement of this milestone.

Under a 2007 agreement between the two companies, Micromet and Nycomed are developing MT203, a human anti-GM-CSF antibody that may be useful for the treatment of various inflammatory and autoimmune diseases. Preclinical studies support development of MT203 for the treatment of rheumatoid arthritis and several other diseases, including multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease.

"Since the start of our collaboration with Nycomed in 2007, we have made excellent progress on the preclinical development of MT203," said Jens Hennecke, Micromet's Senior Vice President of Business Development. "The filing of the CTA represents an important milestone and we are looking forward to the start of clinical trials with MT203."

About Micromet

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells.
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... that it has received final approval for its common shares ... Exchange (the "TSX"). The Company,s common shares will commence trading ... under the trading symbol ,EPI,.  Concurrently, ESSA,s common shares will ... About ESSA Pharma Inc. ESSA Pharma is a ...
(Date:7/28/2015)... 2015 According to a new market ... Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration ... to 2020", published by MarketsandMarkets, the European Injectable Drug Delivery ... $114.7 Billion in 2015, growing at a CAGR of 12.6% ... 230 market data T ables and ...
(Date:7/27/2015)... and PARIS , July ...  and Sanofi have entered into a new global ... treatments in the emerging field of immuno-oncology. As part ... a programmed cell death protein 1 (PD-1) inhibitor currently ... trials in 2016 with new therapeutic candidates based on ...
Breaking Medicine Technology:ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8
(Date:7/28/2015)... ... July 28, 2015 , ... Please join us for the 5th Annual Step for ... located at Gary Avenue and Lies Road in Carol Stream. All are welcome. , ... and provide education and help to support individuals and families affected by a brain aneurysm. ...
(Date:7/28/2015)... ... July 28, 2015 , ... One of the most common ... is plantar fasciitis . Zensah, the Miami-based compression brand, offers a product ... athletic trainer, the Zensah Ankle Support’s primary benefits include helping support the ankle, ...
(Date:7/28/2015)... ... July 28, 2015 , ... Intellitec Solutions has been named by ... of Value Added Resellers of ERP Software is a look at the firms that ... honor represents the second such award in 2015 for Intellitec Solutions, following being named ...
(Date:7/28/2015)... ... 28, 2015 , ... Headaches are the number one neurological ailment affecting people ... suffering from headaches and back pain often find relief by seeking regular treatment from ... 's nine offices in the St. Louis area welcome new clients to try the ...
(Date:7/28/2015)... TN (PRWEB) , ... July 28, 2015 , ... ... of the post surgical spine patient with discussion and demonstration of specific rehabilitation ... . Gain insight into the actual surgical process with an extensive interview conducted ...
Breaking Medicine News(10 mins):Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2Health News:The Joint St. Louis Offers “2 for Thursday” Special, Chiropractic Care Services, Affordable Back Pain Relief 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 3Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 5Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 6
... who were suicidal has highlighted the main challenges they face when ... decide what they should do about it. The research was ... Medicine and Dentistry, supported by Devon NHS Partnership Trust and funded ... the British Medical Journal on 22nd October 2011 (online ...
... Baltimore, MD Oct. 20, 2011. Researchers warn of a ... and home foreclosures. The study, released today in the ... survey of the impact the current housing crisis is having ... 50 and found high rates of depression among those behind ...
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Oct. 20 ... on your mortgage payments hurts more than just your finances, ... struggle can also harm your physical and psychological health. ... 2,500 Americans who took part in the Health and Retirement ...
... , THURSDAY, Oct. 20 (HealthDay News) -- Female drivers ... vehicle crashes, possibly because of a lack of vehicle safety ... the study, the researchers examined crash data from across the ... whether driver gender influenced injury risk. Forty-three percent of the ...
... -- Robins play a major role in the transmission of West ... that carry the virus, new research finds. West Nile virus ... and is now well established throughout North and South America. Although ... key species of birds and mosquitoes play the major role in ...
... University and physicians from Emory University are going to test ... critically ill patient is about to worsen, and more importantly, ... to arm doctors with a forecasting tool," said Rice,s Michael ... from the National Institutes of Health (NIH). "To forecast the ...
Cached Medicine News:Health News:Study highlights issues faced by friends and family of the suicidal 2Health News:Emerging public health crisis linked to mortgage default and foreclosure 2Health News:Emerging public health crisis linked to mortgage default and foreclosure 3Health News:Foreclosure Crisis Threatening Americans' Health: Study 2Health News:Foreclosure Crisis Threatening Americans' Health: Study 3Health News:Car Crash Injury Risk Greater for Women Drivers: Study 2Health News:Robins Are 'Super-Spreaders' of West Nile Virus, Expert Says 2Health News:Cloudy with a chance of sudden death 2Health News:Cloudy with a chance of sudden death 3
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... a key participant in the area of ... decade. Previous Medtronic autotransfusion systems allowed clinicians ... well as to determine requirements for a ... (PRP) for a small amount of autologous ...
... SJM Pericardial Patch with EnCap technology ... vessel reconstruction/repair and for pericardial closure. ... offers surgeons durability and flexibility, plus ... patches. Equally important in a tissue ...
... triaxial catheter design and ergonomic handle ... proprietary radiopaque Nitinol markers on the ... stent enhance visibility. Corrugated ring design ... the nested ring pattern minimizes stent ...
Medicine Products: